ArticleScience (New York, N.Y.)2017
ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice.
Article in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 210 citations in OpenAlex.
- The Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challenges.Cardiovascular drugs and therapy · 2026Review
- Apelin-APLNR pathway across development, inflammation, and vascular remodeling: an endothelial perspective.Experimental & molecular medicine · 2026Review
- Hypoxia-Induced PTPRN2 Suppresses Trophoblast Invasion via Wnt/β-Catenin Pathway Inhibition.Current medical science · 2026Article
- ELABELA Targets Mitochondria to Modulate Heart Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- International Union of Basic and Clinical Pharmacology. CXXI. Apelin receptor pharmacology in the human cardiovascular system and emerging clinical applications.Pharmacological reviews · 2026Review
- ELABELA: A Potential Therapeutic Target for Ischemia-Reperfusion Injury.Biomolecules · 2026Review
- Review
- Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026Review
- Role and therapeutic potential of elabela in renal disease: from molecular mechanisms to clinical applications.Endocrine connections · 2025Review
- Elabela as a predictive biomarker for placenta accreta spectrum: a case-control study.BMC pregnancy and childbirth · 2025Article
- Dad's Diet Shapes the Future: How Paternal Nutrition Impacts Placental Development and Childhood Metabolic Health.Molecular nutrition & food research · 2025Review
- mScience China. Life sciences · 2025Article
- Hydrogen sulfide in placental development and pregnancy disorders: mechanisms, therapeutic potential, and translational challenges.Reproductive biology and endocrinology : RB&E · 2025Review
- ELABELA-32 Alleviates Doxorubicin-Induced Chronic Cardiotoxicity by Inhibiting the TGF-β/Smad Signaling Pathway.Cardiovascular toxicology · 2025Article
- Feto-placental blood vessel development.Development (Cambridge, England) · 2025Review
- Article
- RSAD2: A pathogenic interferon-stimulated gene at the maternal-fetal interface of patients with systemic lupus erythematosus.Cell reports. Medicine · 2025Article
- Axl deficiency promotes preeclampsia and vascular malformations in mice.Molecular therapy. Nucleic acids · 2025Article
- ELABELA: a polypeptide with therapeutic potential in cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Fc-Elabela mitigates heart failure without liver and renal toxicity in mice.Frontiers in pharmacology · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is a gestational hypertensive syndrome affecting between 5 and 8% of all pregnancies. Although PE is the leading cause of fetal and maternal morbidity and mortality, its molecular etiology is still unclear. Here, we show that ELABELA (ELA), an endogenous ligand of the apelin receptor (APLNR, or APJ), is a circulating hormone secreted by the placenta.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.